Allspring Global Investments Holdings LLC Buys 2,516 Shares of Takeda Pharmaceutical Company Limited (NYSE:TAK)

Allspring Global Investments Holdings LLC boosted its stake in Takeda Pharmaceutical Company Limited (NYSE:TAK) by 14.2% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 20,275 shares of the company’s stock after acquiring an additional 2,516 shares during the period. Allspring Global Investments Holdings LLC’s holdings in Takeda Pharmaceutical were worth $269,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also bought and sold shares of the company. FMR LLC boosted its position in shares of Takeda Pharmaceutical by 10.9% during the 3rd quarter. FMR LLC now owns 2,908,918 shares of the company’s stock valued at $41,365,000 after acquiring an additional 286,052 shares during the last quarter. Stifel Financial Corp raised its position in shares of Takeda Pharmaceutical by 103.9% in the 3rd quarter. Stifel Financial Corp now owns 440,666 shares of the company’s stock worth $6,266,000 after acquiring an additional 224,594 shares in the last quarter. Summit Global Investments increased its position in Takeda Pharmaceutical by 86.0% during the 3rd quarter. Summit Global Investments now owns 415,558 shares of the company’s stock valued at $5,909,000 after buying an additional 192,143 shares in the last quarter. Crossmark Global Holdings Inc. lifted its position in Takeda Pharmaceutical by 284.9% in the 4th quarter. Crossmark Global Holdings Inc. now owns 210,484 shares of the company’s stock valued at $2,787,000 after acquiring an additional 155,795 shares in the last quarter. Finally, Van ECK Associates Corp raised its stake in Takeda Pharmaceutical by 6.6% during the 3rd quarter. Van ECK Associates Corp now owns 2,175,236 shares of the company’s stock valued at $30,149,000 after buying an additional 134,407 shares during the last quarter. 9.17% of the stock is owned by institutional investors.

Takeda Pharmaceutical Stock Up 2.0 %

TAK opened at $14.36 on Wednesday. Takeda Pharmaceutical Company Limited has a 1-year low of $12.57 and a 1-year high of $15.08. The company has a current ratio of 1.31, a quick ratio of 0.72 and a debt-to-equity ratio of 0.63. The company has a market capitalization of $45.68 billion, a PE ratio of 35.89, a PEG ratio of 0.24 and a beta of 0.51. The firm’s 50 day simple moving average is $13.33 and its two-hundred day simple moving average is $13.88.

Takeda Pharmaceutical (NYSE:TAK) last posted its quarterly earnings results on Thursday, January 30th. The company reported $0.42 EPS for the quarter, topping analysts’ consensus estimates of $0.34 by $0.08. Takeda Pharmaceutical had a return on equity of 9.39% and a net margin of 4.53%. As a group, equities analysts forecast that Takeda Pharmaceutical Company Limited will post 1.64 EPS for the current year.

Takeda Pharmaceutical Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.